Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nanogen reverse merges with Elitech in €66.5mm deal

Executive Summary

Nanogen has agreed to reverse merge with fellow in vitro diagnostics player Elitech Group (privately held) in a transaction valued at €66.5mm ($99.2mm). The deal excludes Elitech's French sales subsidiary, which the combined entity has the exclusive right to buy for €3.5mm over the next two years.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Hematology, Coagulation
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies